Kronox Lab Sciences Limited IPO
They are a leading manufacturer of High Purity Specialty Fine Chemicals, catering to a wide array of end-user industries. Their portfolio includes over 185 products, including phosphate, sulfate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, and gluconate, among others. Their products are distributed both domestically and internationally, reaching customers in India and over 20 countries globally.
Product Applications
Their High Purity Specialty Fine Chemicals are integral to numerous industries and applications:
i. Pharmaceutical Industry:
Active Pharmaceutical Ingredients (APIs): Their chemicals are used as reacting agents and raw materials in the manufacturing of APIs.
Excipients: They serve as excipients in pharmaceutical formulations, ensuring the stability and efficacy of drugs.
ii. Scientific Research and Laboratory Testing: Their chemicals are utilized as reagents, facilitating various scientific experiments and laboratory tests.
iii. Nutraceuticals: Their ingredients enhance nutraceutical formulations, contributing to health and wellness products.
iv. Biotechnology: They act as process intermediates and fermenting agents in biotech applications, supporting advancements in the field.
v. Agrochemicals: Their products are key ingredients in agrochemical formulations, aiding in agricultural productivity and crop protection.
vi. Personal Care: They supply ingredients for personal care products, ensuring quality and safety in skincare and cosmetic products.
vii. Metal Refining: Their chemicals function as refining agents in metal refineries, playing a crucial role in metal purification processes.
viii. Animal Health: Their ingredients are used in formulations for animal health products, promoting the well-being of livestock and pets.
Commitment to Innovation and Quality
Their commitment to product development, diversity in offerings, and adherence to quality standards has earned them repeat orders and long-standing relationships with their customers. Continuous process improvement and innovation are at the core of their operations, ensuring they remain at the forefront of the industry.
By focusing on these core areas, they aim to provide their customers with reliable, high-quality specialty chemicals that drive their success and growth.
Objects of the Kronox Lab Sciences Limited IPO:
Kronox Lab Sciences Limited IPO Details:
Open Date: | Jun 03 2024 |
Close Date: | Jun 05 2024 |
Total Shares: | 9,570,000 |
Face Value: | ₹ 10 Per Equity Share |
Issue Size: | 130.15 Cr. |
Lot Size: | 110 Shares |
Issue Price: | ₹ 129 - 136 Per Equity Share |
Listing At: | NSE,BSE |
Listing Date: | Jun 10 2024 |
Promoters And Management:
Financials of Kronox Lab Sciences Limited IPO:
Particular (In Million) | Mar-21 | Mar-22 | Mar-23 | 9M-FY24 |
Equity Share Capital | 2.41 | 2.41 | 371.04 | 371.04 |
Reserves | 266 | 401 | 76 | 232 |
Borrowings | 0.1 | 6 | 0 | 0 |
Trade Payables | 66 | 115 | 78 | 57 |
Other Liabilities | 43 | 43 | 15 | 10 |
Total Liabilities | 376 | 568 | 540 | 670 |
Net Block | 57 | 88 | 159 | 260 |
Capital Work in Progress | 4 | 0 | 0 | 0.4 |
Investments | 0.3 | 0.3 | 0.3 | 0.3 |
Other Assets | 53 | 38 | 39 | 7 |
Total NC Assets | 114 | 126 | 199 | 267 |
Receivables | 154 | 258 | 186 | 170 |
Inventory | 55 | 75 | 92 | 72 |
Cash & Bank | 21 | 28 | 36 | 16 |
Other Assets | 32 | 80 | 29 | 145 |
Face value | 10 | 10 | 10 | 10 |
Particular (In Million) | Mar-21 | Mar-22 | Mar-23 | 9M-FY24 |
Sales | 625 | 822 | 956 | 677 |
Cost of materials consumed | 344 | 480 | 580 | 328 |
Change in Inventory | 0 | -6 | -31 | 26 |
Employee Cost | 54 | 57 | 70 | 50 |
Other Expenses | 79 | 94 | 117 | 68 |
Other Income | 8 | 11 | 19 | 8 |
EBITDA | 156 | 208 | 239 | 212 |
EBITDA Margin | 24.94% | 25.28% | 25.02% | 31.34% |
Depreciation | 20 | 20 | 15 | 10 |
Interest | 4 | 4 | 1 | 0 |
Profit before tax | 132 | 184 | 223 | 202 |
Tax | 35 | 47 | 57 | 47 |
Net profit | 97 | 136 | 166 | 155 |
NPM (%) | 15.39% | 16.35% | 17.04% | 22.60% |
Particular (In Million) | Mar-21 | Mar-22 | Mar-23 | 9M-FY24 |
Cash From Operating Activity | ||||
Profit From Operation | 154 | 207 | 235 | 210 |
Receivable | 0.02 | -104 | 73 | 16 |
Inventory | -5 | -20 | -17 | 20 |
Payable | -4 | 55 | -37 | -29 |
Other WC Items | 3 | -0.1 | 1 | -13 |
Working Capital Changes | -5 | -69 | 20 | -6 |
Direct Taxes | 36 | 48 | 58 | 51 |
Net Cash Inflow from Operating Activity | 113 | 90 | 197 | 153 |
Cash from Investing Activity | ||||
Fixed assets purchased | -17 | -38 | -84 | -111 |
Fixed assets sold | 0.8 | 0.8 | 0.2 | 0 |
Other investing items | -14 | -39 | 29 | -62 |
Net cash inflow from investing activities | -30 | -76 | -55 | -173 |
Cash from Financing Activity | ||||
Proceeds from borrowings | -0.1 | 6 | 0 | 0 |
Intrest paid fin | -4 | -4 | -1 | 0 |
Financial liabilities | -8 | -9 | -8 | 0 |
Buy Back of Shares | -59 | 0 | -125 | 0 |
Other financing items | 0 | 0 | -0.01 | 0 |
Net Cash Flow | 13 | 8 | 8 | -20 |
Comparison With Peers:
Name of the Company | Revenue (In Crore) | PAT (In Crore) | EPS ( in Rs) | P/E | CMP | Mcap (In Crore) |
Kronox Lab Sciences Limited | 96 | 17 | 4.47 | 30.4 | 136 | 505 |
Tatva Chintan Pharma Chem Limited | 424 | 45 | 20.52 | 83.7 | 1087 | 2,539 |
Tanfac Industries Limited | 375 | 56 | 56.27 | 37.6 | 1,980 | 1,975 |
Neogen Chemicals Limited | 686 | 50 | 20.04 | 112.0 | 1,512 | 3,991 |
Sigachi Industries Limited | 302 | 44 | 1.42 | 36.1 | 63.8 | 2,062 |
DMCC Speciality Chemical Limited | 385 | 7 | 2.75 | 65.9 | 305 | 763 |
Recommendation on Kronox Lab Sciences Limited IPO:
Lead Manager of Kronox Lab Sciences Limited IPO:
Registrar of Kronox Lab Sciences Limited IPO:
Company Address:
Discussion on Kronox Lab Sciences Limited IPO:
Leave a Reply
You must be logged in to post a comment.